- Home
- SPGC vs REVB Comparison
SPGC vs REVB Comparison
Compare SPGC & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPGC
- REVB
- Stock Information
- Founded
- SPGC 2018
- REVB 2020
- Country
- SPGC United States
- REVB United States
- Employees
- SPGC N/A
- REVB N/A
- Industry
- SPGC
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- SPGC
- REVB Health Care
- Exchange
- SPGC Nasdaq
- REVB Nasdaq
- Market Cap
- SPGC 2.6M
- REVB 2.3M
- IPO Year
- SPGC 2023
- REVB N/A
- Fundamental
- Price
- SPGC $0.66
- REVB $4.31
- Analyst Decision
- SPGC
- REVB
- Analyst Count
- SPGC 0
- REVB 0
- Target Price
- SPGC N/A
- REVB N/A
- AVG Volume (30 Days)
- SPGC 22.4M
- REVB 175.9K
- Earning Date
- SPGC 03-17-2025
- REVB 03-21-2025
- Dividend Yield
- SPGC N/A
- REVB N/A
- EPS Growth
- SPGC N/A
- REVB N/A
- EPS
- SPGC N/A
- REVB N/A
- Revenue
- SPGC $2,491,000.00
- REVB N/A
- Revenue This Year
- SPGC $912.03
- REVB N/A
- Revenue Next Year
- SPGC $49.80
- REVB N/A
- P/E Ratio
- SPGC N/A
- REVB N/A
- Revenue Growth
- SPGC 840.00
- REVB N/A
- 52 Week Low
- SPGC $0.26
- REVB $3.34
- 52 Week High
- SPGC $6.97
- REVB $69.44
- Technical
- Relative Strength Index (RSI)
- SPGC 51.47
- REVB 40.86
- Support Level
- SPGC $0.35
- REVB $3.80
- Resistance Level
- SPGC $1.34
- REVB $4.54
- Average True Range (ATR)
- SPGC 0.22
- REVB 0.37
- MACD
- SPGC 0.03
- REVB 0.18
- Stochastic Oscillator
- SPGC 31.57
- REVB 68.13
About SPGC Sacks Parente Golf Inc.
Sacks Parente Golf Inc is a technology-forward golf company, with a growing portfolio of golf products, including putting instruments, golf shafts, golf grips, and other golf-related products. It designs, manufactures, and sells technology-forward, golf equipment, which is comprised of putting instruments, golf shafts, golf grips, and related product groups. It designs its golf products to fit golfers of all skill levels, amateur and professional. Its business segments currently include, golf putting instruments, golf shafts, and golf related products.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).